RecruitingNCT05570812
Pregnenolone or placebo for depression in people with HIV
About this title
Read the official source — NCT05570812Medication studyAges 18–85United States
Understand this study
Who could participate?
Listed age limits: 18 years to 85 years.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 3, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 120
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 85 Years
- Official registry ID
- NCT05570812
- Official title
Show the full official title
In Vivo Targeting of Neuroactive Steroid and Immune Networks for Depression in People Living With HIV
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Placebo and Pregnenolone.
Who can participate?
Listed age limits: 18 years to 85 years.
Is this study still recruiting?
The registry lists this study as recruiting.
